Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 12
Phase 22

Trial Status

Completed2

Role Distribution

Principal Investigator2
PI Rate100%

Activity Timeline

Clinical Trials (2)

NCT03356860Phase 1/2Completed
Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer.
Breast CancerLuminal BTriple Negative Breast Cancer
PrincipalinvestigatorStart date: 2017-04-13

Research Network

Collaboration Network

4 collaborators·4 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Research Areas & Affiliations

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

François Duhoux, MD, PhD

Cliniques universitaires Saint-Luc (UCL)

Moderately Similar
1 trials

Shared therapeutic areas:

Breast CancerLuminal BTriple Negative Breast Neoplasms

Worked with same sponsors:

Cliniques universitaires Saint-Luc- Université Catholique de LouvainGrand Hôpital de Charleroi
Collaborated on 1 trial
Similarity Score34%

Jean-Luc Canon, MD

GHdC

Moderately Similar
1 trials

Shared therapeutic areas:

Breast CancerLuminal BTriple Negative Breast Neoplasms

Worked with same sponsors:

Cliniques universitaires Saint-Luc- Université Catholique de LouvainGrand Hôpital de Charleroi
Collaborated on 1 trial
Similarity Score34%

Lizhi Niu, PhD

Fuda Cancer Hospital

Related
31 trials

Shared therapeutic areas:

Breast CancerRectal Neoplasms
Similarity Score15%

Michael B Gill

Power Life Sciences Inc.

Related
105 trials

Shared therapeutic areas:

Breast CancerTriple Negative Breast Neoplasms
Similarity Score15%

Norman Wolmark, MD

NSABP Foundation Inc

Related
54 trials

Shared therapeutic areas:

Breast CancerTriple Negative Breast Neoplasms
Similarity Score15%

Marc Van den Eynde, MD, PhD

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Related
1 trials

Shared therapeutic areas:

Rectal Neoplasms

Worked with same sponsors:

Cliniques universitaires Saint-Luc- Université Catholique de LouvainGrand Hôpital de Charleroi
Collaborated on 1 trial
Similarity Score14%

Herui Yao, PhD

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Related
11 trials

Shared therapeutic areas:

Breast Cancer
Similarity Score8%

Dong-Xin Wang, MD, PhD

Peking University First Hospital

Related
74 trials

Shared therapeutic areas:

Breast Cancer
Similarity Score8%

Ali MA Ismail, lecturer

Cairo University

Related
27 trials

Shared therapeutic areas:

Breast Cancer
Similarity Score8%

Steven A Rosenberg, M.D.

National Cancer Institute (NCI)

Related
32 trials

Shared therapeutic areas:

Breast Cancer
Similarity Score8%

Publications (0)

No publications found for this investigator.

Clinical Trials (2)

Showing 2 of 2 trials

NCT03127007Phase 1/2PrincipalInvestigator

Safety and Efficacy of Atezolizumab Combined to Preoperative Radio-chemotherapy in Localized Rectal Cancer

Rectal Neoplasms
Completed
NCT03356860Phase 1/2PrincipalInvestigator

Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer.

Breast CancerLuminal BTriple Negative Breast Cancer
Completed

All 2 trials loaded